• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anika beats Q4 earnings, revenue estimates

February 16, 2017 By Sarah Faulkner

Anika beats Q4 earnings, revenue estimatesShares in Anika Therapeutics (NSDQ:ANIK) fell today, even though the orthopedic medicines company beat expectations on Wall Street with its 4th quarter results.

The Bedford, Mass.-based company posted profits of $8.1 million, or 54¢ per share, on sales of $28.7 million for the 3 months ended Dec. 31, for bottom-line loss of -26% on sales loss of -7% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 54¢, a penny ahead of consensus on The Street, where analysts were looking for sales of $27.8 million.

“Anika delivered another year of very strong growth, with 17% product revenue growth for the full year of 2016,” president & CEO Charles Sherwood said in prepared remarks. “We also submitted an IND application to the FDA to initiate an additional Phase III clinical trial of Cingal, and we received CE Mark approval for Orthovisc-T in the 4th quarter, paving the way for our next generation of growth drivers. We expect to commence the Cingal Phase III trial and launch Orthovisc-T in Europe in the first half of 2017. Our strategic objectives in 2017 are focused on global commercial expansion, pipeline advancement, infrastructure enhancements and strategic M&A to drive sustained growth and create value for patients and shareholders.”

Anika said it expects total revenue growth to be in the mid-teen percent range for 2017.

ANIK shares were trading at $48.87 apiece today in morning trading, down -6.4%.

In December, the company won CE Mark approval in the European Union for its Orthovisc-T injection. Anika’s treatment is indicated to relieve pain and restore function in tendons affected by tennis elbow, or chronic lateral epicondylosis.

The sodium hyaluronate injection promotes tendon gliding and repair at the site of the damaged tissue, according to Anika.

The company won CE Mark approval in the European Union for its Cingal drug-combo designed to treat osteoarthritis-related knee pain in March last year.

Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, Anika said.

Filed Under: Featured, MassDevice Earnings Roundup, Orthopedics Tagged With: Anika Therapeutics Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS